News

The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome – research into

The Australian federal court ruled that Nurofen’s varieties for back pain, period pain, migraine pain and tension headaches were all found to feature the same active ingredient, 342

Patients with ALS fatal neurodegenerative disorder suffer progressive degeneration of the motor neurons, which leads to a declining quality of life and even could lead to death, the

Vistogard is claimed to be the first antidote for emergency treatment of 5-fluorouracil (5-FU) overdose treatment available to patients. It is also indicated for patients exhibiting early-onset, severe

The meeting with the FDA concerned the company’s cell-based product for the treatment of ALS. The response received on December 9, 2015 from the FDA represents a summary

"The ADAPT phase 3 trial to evaluate AGS-003 in front line mRCC, the largest global trial ever performed in newly diagnosed, unfavorable risk mRCC patients, continues to progress

If approved, the sNDA would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus

The Company is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases. TD-1473 is an internally-discovered JAK inhibitor that has

NuSirt also announced the start of enrollment for its Phase 2A clinical trial targeting this disease at nine U.S. research sites. NuSirt Biopharma president and executive chairman of